All of these findings showed that miRNA-34a inhibited invasion, TGF-induced, and migration of NPC cells by directly targeting SMAD4, suggesting that miR-34a may be used as a targeted therapy for NPC. This evidence concerns the gene SMAD4 and nasopharyngeal carcinoma.